Review Article
B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia
Table 1
Overview of BAFF receptors.
| | Gene | Forms | Ligands | Affinity to BAFF () | Tissue expression | Function | Clinical relevance |
| BAFF-R (BAFF-receptor, TNFRSF13C, BLyS, BR3, CD268) [13] | 22q13.2 3 exons [13] | Membrane bound, soluble (produced by decidual cells) [8, 14] | BAFF [8] | 16 nmol·l−1 [8] | B-, T-cells [15, 16] mature and immature adipose tissue [17] | B-cell proliferation [18], T-cell proliferation [16] | BAFF-R is constitutively saturated in autoimmune and lymphoproliferative diseases [15, 19, 20] |
| TACI (transmembrane activator and calcium signal-modulating cyclophilin ligand, TNFRSF13B, CD267) [21] | 17p11.2 5 exons [21] | Membrane bound [8] | BAFF, APRIL [8] | 146 nmol·l−1 [22] | B-, T-cells immature adipose tissue [17] | T-cell activation [23] and humoral immunity response modulation [24, 25] | Mutations may result in common variable immunodeficiency [26, 27] |
| BCMA (B-cell maturation antigen, TNFRSF17) [28] | 16p13.1 3 exons [28] | Membrane bound [8] | APRIL (BAFF) [8] | 1600 nmol·l−1 [8] | B-cells immature [17] | Long-term plasma cell survival, B-cell antigen presentation [29] | Protection of multiple myeloma cells from apoptosis [30, 31] |
|
|